  Biomedical data, particularly in the field of genomics, has characteristics
which make it challenging for machine learning applications - it can be sparse,
high dimensional and noisy. Biomedical applications also present challenges to
model selection - whilst powerful, accurate predictions are necessary, they
alone are not sufficient for a model to be deemed useful. Due to the nature of
the predictions, a model must also be trustworthy and transparent, empowering a
practitioner with confidence that its use is appropriate and reliable. In this
paper, we propose that this can be achieved through the use of judiciously
built feature sets coupled with Bayesian models, specifically Gaussian
processes. We apply Gaussian processes to drug discovery, using inexpensive
transcriptomic profiles from human cell lines to predict animal kidney and
liver toxicity after treatment with specific chemical compounds. This approach
has the potential to reduce invasive and expensive animal testing during
clinical trials if in vitro human cell line analysis can accurately predict
model animal phenotypes. We compare results across a range of feature sets and
models, to highlight model importance for medical applications.
